Connect Biopharma Holdings stock analysis
Want to see CNTB full AI Analyst Report?
Connect Biopharma Holdings (CNTB) Stock Price & Analysis
CNTB Stock Chart & Stats
- Day’s Range
- $0.56 - $0.67
- 52-Week Range
- $0.55 - $3.82
- Previous Close
- $0.58
- Volume
- N/A
- Average Volume (3M)
- 794.01K
- Market Cap
- $37.33M
- Enterprise Value
- $118.77M
- Total Cash (Recent Filing)
- $31.49M
- Total Debt (Recent Filing)
- $596.00K
- Price to Earnings (P/E)
- ―
- Beta
- -0.25
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.19
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Phase 2 COPD Efficacy
The Phase 2 COPD results provide meaningful clinical validation for rademikibart, including lower treatment failures, exacerbations, and hospital or emergency visits. If confirmed in later development, these outcomes could support differentiation and expand the company’s respiratory pipeline opportunity.
Phase 2 Asthma Efficacy
Positive asthma data broaden the clinical case for rademikibart across related respiratory indications. The observed lung-function improvement and fewer treatment failures support continued development, while the reported placebo-comparable safety profile may help the program progress toward later-stage testing.
Low Debt Balance Sheet
Very low debt reduces fixed financing obligations and limits interest-related pressure while the company advances clinical programs. This gives management more flexibility than a highly leveraged balance sheet, although continued losses still make preservation of financial resources important.
Bears Say
Zero Revenue And Large Losses
The absence of revenue and substantial net losses show that the company has not yet established a durable commercial earnings base. Continued dependence on clinical progress rather than product sales leaves results vulnerable to development setbacks and limits internally generated funding.
Persistent Cash Burn
Persistent operating and free-cash-flow deficits require the company to fund research and corporate activities from existing resources or external capital. Unless spending falls or revenue is rebuilt, ongoing burn can restrict development choices and increase financing pressure over the coming quarters.
Nasdaq Bid-price Compliance Risk
The minimum bid-price notice creates an ongoing listing-compliance issue through the stated cure period, even though trading was not immediately affected. Failure to regain compliance could add operational distraction and market-access uncertainty while the company remains financially loss-making.
Connect Biopharma Holdings News
Buy Rating Reiterated on Rademikibart’s Acute COPD Potential and Seabreeze Data, with Unchanged $7 Price Target
In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings, with a price target of $7.00. Brandon Folkes has given his Buy
Connect Biopharma announces results from global Phase 2 study of rademikibart
Connect Biopharma (CNTB) announced topline results from its global Phase 2 study evaluating rademikibart, the Company’s next-generation, potentially best-in-class anti-interleukin-4-receptor alpha antibody as an add-on treatment for acute exacerbations in
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
What is Connect Biopharma Holdings’s market cap?
When is Connect Biopharma Holdings’s upcoming earnings report date?
How were Connect Biopharma Holdings’s earnings last quarter?
Is Connect Biopharma Holdings overvalued?
Does Connect Biopharma Holdings pay dividends?
What is Connect Biopharma Holdings’s EPS estimate?
How many shares outstanding does Connect Biopharma Holdings have?
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
What is the TipRanks Smart Score and how is it calculated?
Connect Biopharma Holdings Stock Smart Score
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Barry D. Quart
- Employees
- 64
- Website
- www.connectbiopharma.com
- Address
- 3580 Carmel Mountain Road, San Diego, CA, 92130, US
Connect Biopharma Holdings (CNTB) Earnings & Revenues
CNTB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 3 | 13 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 2 | 0 | 10 |












